anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 \& 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 \& 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 \& so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, \& so on). Bortezomib will be administered at 1.3 mg/m\^2 SC/IV on Days 1,4,8, \& 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, \& 12 of every 21-day cycle.
IMPORTANCE: The associated effect of duration of the second stage of labor (SSL) on pelvic floor symptoms development is not well studied.
OBJECTIVE: This study aimed to examine the association between duration of SSL and pelvic floor symptoms at 6 months postpartum among primiparous women.
STUDY DESIGN: A planned secondary analysis of a multicenter randomized trial evaluating the impact of immediate versus delayed pushing on vaginal delivery rates, maternal morbidity, and neonatal outcomes was conducted between 2014 and 2018. For pelvic floor arm participants, demographic, pelvic examination, and validated questionnaire data were collected postpartum. Primary outcome was change in Pelvic Floor Distress Inventory 20 (PFDI-20) score from immediate to 6 months postpartum. Secondary outcomes included changes in the Pelvic Floor Impact Questionnaire, Fecal Incontinence Severity Index, Modified Manchester Health Questionnaire scores, and Pelvic Organ Prolapse Quantification measurements at 6 months postpartum. Participants were analyzed by SSL duration ≤60 minutes or >60 minutes.
RESULTS: Of the 2,414 trial participants, 767 (32%) completed pelvic floor assessments at 6 months. Pelvic Floor Distress Inventory 20 scores significantly improved at 6 months in the ≤60 minutes SSL group compared with >60 minutes SSL (-14.3 ± 48.0 and -3.2 ± 45.3, respectively; P = 0.04). Changes from immediate postpartum in total and subscale scores for other questionnaires at 6 months did not differ between groups. Prolapse stage did not differ between groups. Perineal body was significantly shorter in the >60 minutes SSL group (3.7 ± 0.7, 3.5 ± 0.8; P = 0.03).
CONCLUSIONS: Women with SSL >60 minutes experience less improvement in PFDI-20 scores at 6 months. Greater tissue and innervation trauma in those with SSL >60 minutes may explain persistently less improvement in PFDI-20 scores.
We hope to enroll 50 high-risk acute leukemia patients after receiving HSCT at China Medical University Hospital. Thereupon, patients will be consecutively recruited to treatment group (25 patients) where they will be prescribed Sheng Yu Tang (聖愈湯, SYT) 2 months following HSCT, for a period of 6 months, in conjunction with the standard-care treatment. We predict that not all patients will be interested in taking SYT, patients which are not interested in entering treatment group will be offered to join a control group (25 patients) which will receive standard-care treatment.

Since HSCT patients go through routine blood examinations, this study will request to extract a further 20ml of peripheral blood once a month and an additional 20ml of bone marrow at beginning of HSCT and the following routine aspirations (est.:0, +3, +6, +9, +12 month). Both treatment and control group will be required to contribute peripheral blood and bone marrow sample.Blood samples will be collected until patients reach 1-year post-HSCT, and flow cytometry will be used to examine the difference in immune reconstitution rate between the two groups. As secondary outcome measurements, this study will make use of the minimal residual disease (MRD) measured, frequency of opportunistic infections, hospitalizations and results of other routine check-up which recorded in patient history.
Octanal was found to be able to reduce green mold incidence in citrus fruit by a defense response mechanism. However, the underlying mechanism remains largely unclear. Herein, the metabolomics, RNA-seq and biochemical analyses were integrated to explore the effect of octanal on disease resistance in harvested citrus fruit. Results showed that octanal fumigation at 40 μL L-1 was effective in controlling citrus green mold. Metabolomics analysis showed that octanal mainly led to the accumulation of some plant hormones including methyl jasmonate, abscisic acid, indole-3-butyric acid, indoleacetic acid (IAA), salicylic acid, and gibberellic acid and many phenylpropanoid metabolites including cinnamyl alcohol, hesperidin, dihydrokaempferol, vanillin, quercetin-3-O-malonylglucoside, curcumin, naringin, chrysin, coniferin, calycosin-7-O-β-D-glucoside, trans-cinnamaldehyde, and 4',5,7-trihydroxy-3,6-dimethoxyflavone. Particularly, IAA and hesperidin were dramatically accumulated in the peel, which might be the contributors to the resistance response. Additionally, transcriptome analysis showed that octanal greatly activated the biosynthesis and metabolism of aromatic amino acids. This was further verified by the accumulation of some metabolites (shikimic acid, tryptophan, tyrosine, phenylalanine, IAA, total phenolics, flavonoids and lignin), increase in some enzyme activities (phenylalanine ammonia-lyase, tyrosine ammonia-lyase, 4-coumarate CoA ligase, cinnamic acid 4-hydroxylase, polyphenol oxidase, and peroxidase), up-regulation of some genes (tryptophan pyruvate aminotransferase, aldehyde dehydrogenase, shikimate kinase and shikimate dehydrogenase) expressions and molecular docking results. Thus, these results indicate that octanal is an efficient strategy for the control of postharvest green mold by triggering the defense response in citrus fruit.
Subjects enrolled in a short-term study (5 years) consisted of cases eligible to receive the LPS-Flex Mobile Bearing Knee implanted by orthopedic surgeons experienced in primary total knee replacement. All Group 2 subjects, both unilateral and bilateral subjects, are in the same arm of the study. As part of the PAS study, these subjects were followed from Pre-operative to 5 years.
NEW MATERIAL:The compound of formula I and formula II. USE:Antibacterial agent. PREPARATION:For example, Streptomyces sp. No.1176 strain (FERM P-No.8135) is inoculated in a culture medium and cultured under shaking to obtain a seed. The seed is transplanted to a large-scale fermentor filled with a culture medium and cultured. The culture product is filtered under pressure in the presence of celite, the filtrate is extracted with a solvent such as butyl acetate, and the extract is concentrated. The extract is added with chloroform, etc., and developed in a silica gel column. The active fraction is concentrated to dryness, dissolved in ethyl acetate, etc., and subjected to gel-filtration with a silica gel column to obtain a fraction containing the compound of formula I and formula II. The fraction is concentrated and dried to obtain the compound of formulae I and II in powdery state.
This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
The present disclosure provides a sustained-release composition including a sodium hydrosulfide and a carrier. The carrier is provided for carrying the sodium hydrosulfide with an effective amount and includes a first component and a second component. The first component includes a paraffin wax, and the second component includes a fatty alcohol, a fatty acid or a phospholipid. The present disclosure also provides a method for fabricating the sustained-release composition. The method includes providing a first solution, providing the carrier, providing a second solution, performing an oil-in-water emulsification, and cooling the emulsion. In addition, the present disclosure provides a method for treating the chronic wounds. The method includes administering an effective amount of the aforementioned sustained-release composition to a subject suffered from the chronic wounds.
The invention provides a polyelectrolyte assembly based on aggregation-induced emission dye, a preparation method and application thereof. The dye is aggregation-induced emission dye with bidentate ligand, and has a structure shown in formula I. The dye is used for dyeingThe material takes the quinoline nitrile derivative as an aggregation-induced emission unit and takes the isophthalic acid and the derivative thereof as a coordination unit, so that the material has the advantages of near infrared fluorescence emission, large Stokes shift, excellent metal coordination, good biocompatibility and the like, and can construct a stable polyelectrolyte assembly. The dye is assembled with a cation-neutral block polymer and metal ions through coordination and electrostatic action to construct a polyelectrolyte assembly. By coordinating different functional metal ions, the polyelectrolyte assembly is capable of achieving multi-mode imaging integration. Such polyelectrolyte assemblies based on aggregation-induced emission dyes have been successfully used for in vivo real-time imaging of tumor mice.
The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin which gives reduced irritation to the skin, gives an enhanced warm sense, and has excellent strength and sustainability of the warm sense, enhanced percutaneous absorption of a non-steroidal antiinflammatory agent as an active ingredient, and excellent sustainability when applied to the skin, by including capsicoside and other substance(s) from red pepper as warm sense-giving substances. SOLUTION: This preparation is obtained by including (A) a non-steroidal antiinflammatory agent (preferably, flurbiprofen and felbinac). (B) capsicoside, and (C) and other substance(s) from red pepper wherein components B and C are warm-sense-giving substances. It is preferable to include component A at 0.3-3 wt.% and sum of components B and C at 0.01-1 wt.%, per the final preparation for external use. It is preferable that the component C/component B weight ratio is 1-100. Preferably the (sum of components B and C)/component A weight ratio is 0.002-0.5.
The present invention relates to an immune potentiator of Marek's disease vaccine for chickens and a preparation method thereof, which belongs to biological preparations. The present invention is characterized in that the potentiator is prepared from proteins and amino acids comprising beef extract, calf blood serum, cow milk, etc., and levamisole. The preparation method comprises: fresh degreased beef is mashed and boiled in water so as to obtain the extract; peptone, sodium chloride, evaporated milk and sucrose are respectively added to the extract; after the peptone, the sodium chloride, the evaporated milk and the sucrose are completely dissolved, the calf blood serum is sterilized under high pressure, and the levamisole is filtered and sterilized; and the extract, the calf blood serum and the levamisole are evenly and proportionally mixed, filled in bottles (2 to 3 ml per bottle) and frozen to be dry so as to obtain the finished product. The potentiator is the carrier of the vaccine, and can provide sufficient nutrition for the vaccine. Therefore, when the vaccine is inoculated at variable temperatures, the content of virus antigens is enhanced by more than 30%. Thus, the potentiator creates obvious social benefit and economic benefit.
Devices, systems, and methods for generating and updating one or more user interfaces of a mobile software application operating on a smart phone of a stroke survivor having an impairment. The method can include tracking a first state of stroke survivor post discharge. The method can also include generating a first user interface configured to be displayed on the smart phone and is dynamically updated based on the tracked first state of the stroke survivor. Further, the method can include a first ribbon in the first user interface corresponding to a first learning content. Moreover, the method can include splitting the learning content based on the impairment associated with the stroke survivor and a first property of the first learning content. Lastly, the method can include a second ribbon in the first user interface corresponding to a second learning content.
The experience of empathy for pain is underpinned by sensorimotor and affective dimensions which, although interconnected, are at least in part behaviorally and neurally distinct. Spinal cord injuries (SCI) induce a massive, below-lesion level, sensorimotor body-brain disconnection. This condition may make it possible to test whether sensorimotor deprivation alters specific dimensions of empathic reactivity to observed pain. To explore this issue, we asked SCI people with paraplegia and healthy controls to observe videos of painful or neutral stimuli administered to a hand (intact) or a foot (deafferented). The stimuli were displayed by means of a virtual reality set-up and seen from a first person (1PP) or third person (3PP) visual perspective. A number of measures were recorded ranging from explicit behaviors like explicit verbal reports on the videos, to implicit measures of muscular activity (like EMG from the corrugator and zygomatic muscles that may represent a proxy of sensorimotor empathy) and of autonomic reactivity (like the electrodermal response and Respiratory Sinus Arrhythmia that may represent a general proxy of affective empathy). While no across group differences in explicit verbal reports about the pain stimuli were found, SCI people exhibited reduced facial muscle reactivity to the stimuli applied to the foot (but not the hand) seen from the 1PP. Tellingly, the corrugator activity correlated with SCI participants' neuropathic pain. There were no across group differences in autonomic reactivity suggesting that SCI lesions may affect sensorimotor dimensions connected to empathy for pain.
The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver transplant patients; therefore, such use is not recommended. The use of sirolimus has been associated with adverse outcomes in patients following liver transplantation, including excess mortality, graft loss and hepatic artery thrombosis (HAT). 

In a study in de novo liver transplant patients, the use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss (22% in combination versus 9% on tacrolimus alone). Many of these patients had evidence of infection at or near the time of death.

In this and another study in de novo liver transplant patients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in HAT (7% in combination versus 2% in the control arm); most cases of HAT occurred within 30 days post-transplantation, and most led to graft loss or death.

In a clinical study in stable liver transplant patients 6-144 months post-liver transplantation and receiving a CNI-based regimen, an increased number of deaths was observed in the group converted to a sirolimus-based regimen compared to the group who was continued on a CNI-based regimen, although the difference was not statistically significant (3.8% versus 1.4%) [see Clinical Studies (14.5)].
The present invention relates to an externally applied medicine for treating femoral head necrosis and a processing method of an externally applied medicine for treating femoral head necrosis. The medicine comprises the following components taking portion by weight as the unit: 1 to 2 portions of Chinese ephedra, 1 to 2 portions of aconitum Chinese paxton, 1.5 to 3 portions of wild aconite, 2 to 4 portions of saffron, 2 to 4 portions of pangolins, 2 to 4 portions of scorpions, 2 to 4 portions of earthworms, 3 to 6 portions of frankincense, 3 to 6 portions of gallnut, 1.5 to 3 portions of coptis, 1.5 to 3 portions of phellodendron barks, 2 to 4 portions of rhubarb, 1.5 to 3 portions of calcined pyritum and 3 to 6 portions of drynaria. The main medicines and the auxiliary medicines are combined together in use. The externally applied medicine for treating femoral head necrosis has the functions of channel warming, blood stasis removal, meridian and collateral clearing, blood circulation promotion, pain alleviation, tissue regeneration promotion, focus vascular lesion elimination, focus microcirculation improvement, fast dead bone absorption promotion, new bone regeneration promotion, cranial cartilage regeneration promotion, focus healing promotion, joint improvement, etc. The externally applied medicine for treating femoral head necrosis dispels pathogenic factors, such as wind, cold, dampness, stasis, etc. The externally applied medicine for treating femoral head necrosis can be used for treating diseases, such as femoral head necrosis, synovitis, osteoarthritis, diskal hernia, long-term bone fracture disunion, etc., caused by various disease causes.
<P>PROBLEM TO BE SOLVED: To provide a composition simply and effectively mitigating whole physical and mental symptoms related to menstruation irrespective of a period before and after menarche.  <P>SOLUTION: The composition comprising an extract from Zingiber officinale Roscoe and an extract from Panax ginseng C.A. Meyer known as Chinese crude drugs in addition to oil of Oenothera tetraptera Cav. and soybean isoflavone used in the West is administered to thereby effectively mitigate the whole symptoms related to the menstruation including physical symptoms such as abdominal pain, lumbago, headache and swelling of the breast and mental symptoms such as an irritable feeling. Furthermore, the period feeling the menorrhalgia is shortened.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
This arm consists of a 2-week, computerized, stress-management condition in which participants watch videos of health habits (e.g., nutrition, exercise, sleep) and relaxation videos. These sessions are completed every 2 days at home (8 sessions total).
Human Experience:In premarketing clinical studies, there were reports of mirtazapine overdose alone or in combination with other pharmacological agents. Signs and symptoms reported in association with overdose included disorientation, drowsiness, impaired memory, and tachycardia. 

Based on postmarketing reports, serious outcomes (including fatalities) may occur at dosages higher than the recommended doses, especially with mixed overdoses. In these cases, QT prolongation and Torsades de Pointes have also been reported [see Warnings and Precautions (5.5), Adverse Reactions (6.2), and Drug Interactions (7)]. 

Overdose Management:No specific antidotes for mirtazapine are known. 

Contact Poison Control (1-800-222-1222) for the latest recommendations.
BACKGROUND: There is growing evidence of bidirectional associations between rheumatoid arthritis and adverse pregnancy outcomes (APOs) in observational studies, but little is known about the causal direction of these associations. Therefore, we explored the potential causal relationships between rheumatoid arthritis and APOs using a bidirectional two-sample Mendelian randomization (MR) in European and Asian populations.
METHODS: We conducted a bidirectional two-sample Mendelian randomization analysis using available summary statistics from released genome-wide association studies. Summary statistics for instrument-outcome associations were retrieved from two separate databases for rheumatoid arthritis and adverse pregnancy outcomes, respectively. The inverse-variance weighted method was used as the primary MR analysis, and cML-MA-BIC was used as the supplementary analysis. MR-Egger, MR pleiotropy residual sum and outlier (MR-PRESSO), and Cochran Q statistic method were implemented as sensitivity analyses approach to ensure the robustness of the results.
RESULTS: Our study showed that a higher risk of rheumatoid arthritis in the European population was associated with gestational hypertension (OR: 1.04, 95%CI: 1.02-1.06), pre-eclampsia (OR: 1.06, 95%CI: 1.01-1.11), fetal growth restriction (OR: 1.08, 95%CI: 1.04-1.12), preterm delivery (OR:1.04, 95%CI: 1.01-1.07). Furthermore, we found no evidence that APOs had causal effects on rheumatoid arthritis in the reverse MR analysis. No association between rheumatoid arthritis and APOs was found in East Asian population. There was no heterogeneity or horizontal pleiotropy.
CONCLUSIONS: This MR analysis provides the positive causal association from rheumatoid arthritis to gestational hypertension, pre-eclampsia, fetal growth restriction and preterm delivery genetically. It highlights the importance of more intensive prenatal care and early intervention among pregnant women with rheumatoid arthritis to prevent potential adverse obstetric outcomes.
The invention provides a decitabine nano-carrier and application thereof in preparing a tumor fluorescence imaging agent. The preparation method comprises emulsifying bovine hemoglobin, fluorescent dye Nile Red, polylactic acid-glycolic acid copolymer, etc., coating chitosan loaded with decitabine and NBD modified chitosan, sterilizing, and making into lyophilized powder. Dissolved in the aqueous phase before use and loaded with oxygen. The invention is based on 769-P and OS-RC-2 renal cancer cell lines, and constructs a hypoxic cell model and a tumor-bearing mouse model. The results show that CNDHNNPs improve hypoxic microenvironment, reduce drug efflux, decitabine increases tumor chemotherapy drug uptake, and sensitization chemotherapy. And catalyzes an increase in lipid peroxidation in combination with iron apoptosis therapy. The invention provides a new scheme and a drug delivery system for targeting tumor hypoxia and hypermethylation combined iron death for treating the kidney cancer and realizes tumor fluorescence imaging. The invention has reasonable design and strong repeatability.